Tirzepatide

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, marketed as Mounjaro and Zepbound by Eli Lilly. It activates both GLP-1 and GIP pathways to enhance insulin secretion, suppress glucagon, reduce appetite, and promote weight loss while improving hepatic and peripheral insulin sensitivity. In the SURPASS clinical trial series, tirzepatide 15mg achieved superior efficacy compared to semaglutide, reducing HbA1c by 2.58% and body weight by 11.7kg, with real-world data confirming significantly greater weight loss than GLP-1 monotherapy. Its notable advantages include greater reductions in liver fat, triglycerides, and insulin resistance compared to single-agonist approaches.

10mg